Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06191146
Other study ID # 2023PI048
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 1, 2024
Est. completion date February 1, 2025

Study information

Verified date February 2024
Source Central Hospital, Nancy, France
Contact charles ZAGOZDA
Phone 0684130446
Email charles-zagozda@hotmail.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

hypothesis = hospitalization in the intensive care unit (ICU) has an impact on the outcome of the renal graft, due to the therapeutic and exploratory procedures performed. the aim is to identify risk factors for renal graft degradation in the ICU up to 2 years after hospitalization. Optimization of renal graft management in the ICU and management by nephrologists after the ICU


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date February 1, 2025
Est. primary completion date January 1, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - kidney graft - > 18 years - first hospitalization in ICU Exclusion Criteria: - chronic hemodialysis before ICU - transfer to intensive care immediately after transplant within 24 hours

Study Design


Locations

Country Name City State
France CHRU Nancy Nancy

Sponsors (1)

Lead Sponsor Collaborator
Central Hospital, Nancy, France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary composite: return to dialysis, decline in GFR < 15 ml/min, death at 2 years Death within 2 years, glomerular filtration rate < 15mL/min, need for dialysis 2 years after ICU
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05031013 - Trace Elements Concentration in Dialysis
Not yet recruiting NCT03090828 - Economic Evaluation of an Education Platform for Patients With End-stage Renal Disease N/A
Completed NCT01685372 - Immunogenicity of Fluzone High Dose in Immunocompromised Children and Young Adults Phase 2
Active, not recruiting NCT01394770 - Aliskiren or Amlodipine in Hypertensive Hemodialysed Patients Phase 4
Completed NCT00506441 - A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia Phase 3
Completed NCT00537979 - Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis Phase 4
Completed NCT05415969 - CKD-aP Among Adults on Dialysis in Switzerland
Recruiting NCT04024007 - Determination of Citrate Clearance Used in Regional Anticoagulation of Continuous Venous Hemofiltration Circuits
Completed NCT03772171 - Estimate for Dietary Intakes and Hemodialysis Patients
Recruiting NCT02586402 - Safety & Efficacy of Pegolsihematide for Treatment of Anemia in Participants on Dialysis Phase 2
Active, not recruiting NCT01693263 - Outcome of BCF Access in Hemodialysis Patients
Completed NCT01421771 - Blood Pressure in Dialysis Patients N/A
Active, not recruiting NCT01065389 - Resistance Training in Intradialysis Patients Phase 2
Completed NCT00544492 - Study of Pain, Anxiety and Complications Related to Cannulation of Arteriovenous (AV) Fistula in Chronic Hemodialysis Patients Phase 4
Completed NCT03910426 - Prognostic Determinants of Survival and Quality of Life in Prevalent End-stage Kidney Disease Patients
Completed NCT04667741 - Post-dialysis Recovery Time and Affecting Factors Between Turkey and Portugal
Completed NCT04565522 - Transmission of COVID-19 Virus Among Patients and Staff in Dialysis Centers
Completed NCT04655989 - A Study to Demonstrate the Safety and Effectiveness of the NIKKISO DBB-EXA ES Hemodialysis Delivery System N/A
Completed NCT05125848 - Clinical Evaluation of the CM-1500 During Hemodialysis N/A
Completed NCT04633915 - Antibody Response in Hemodialysis and Non-dialysis Patients Diagnosed With COVID-19.